APVO

Aptevo Therapeutics Inc.

0.80 USD
-0.00 (-0.19%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Aptevo Therapeutics Inc. stock is up 9.38% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 7 May’s closed higher than April.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company also has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.